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DOI 10.1016/j.chembiol.2010.06.005In 2003, several program leaders within
the National Institutes of Health (NIH) re-
cognized that the results from the recently
completed Human Genome Project were
a launching pad for further study. Now
that scientists knew the genome, how
could they determine gene function? In
particular, how could scientists find
specific biological pathways and targets
that could lead to newadvances in biology
and new drug therapies?
TheMolecular Libraries Program (MLP),
an NIH Roadmap Initiative first funded in
2004, has partially answered those ques-
tions. ‘‘At the time the term ‘chemical
genomics’ was on the minds of NIHMLP was founded to fund research spanning multiple NIH insti-
tutes, all with one goal: identify new chemical probes to explore
new targets for drug therapies.researchers,’’ explains Carson Loomis,
Ph.D., Program Director, Molecular
Libraries. ‘‘The human genome was avail-
able and it was agreed that the NIH should
become more involved in screening new
small molecules to get better targets.’’
The pharmaceutical industry had become
frustrated by drug failures in development
lacking the means to sufficiently validate
potential targets. ‘‘They were at the
breaking edge of science, yet when
a new kinase was discovered and they
developed a drug for it, it would often
fail,’’ explains Loomis. ‘‘The feeling was
that we needed more basic research and
that the NIH needed to further this cause
of validating targets.’’
The act of Congress creating the MLP
now includes the efforts of nine Molecular
Libraries Probe Production Centers. They
include one intramural NIH site, the
National Center for Chemical Genomics
(NCGC), and eight extramural sequencing
and screening centers: the Broad Insti-
tute, the Sanford-Burnham Medical Re-
search Institute, Johns Hopkins Univer-sity, Scripps Research Institute, the
University of New Mexico, Southern
Research Institute, the University of Kan-
sas, and Vanderbilt University.
The common purpose of these probe
production centers is to generate new
small molecule chemical probes by per-
forming high throughput screening,
secondary screens, and medicinal chem-
istry. The biological assays for these
probes are sourced from the scientific
community at large.
MLP was founded to fund research
spanning multiple NIH institutes, all with
one goal: identify new chemical probes
to explore new targets for drug therapies.Screening Library
The workhorse of the MLP program is
its 350,000-strong library of unique chem-
ical structures of the NIH’s Molecular
Libraries Small Molecule Repository
(MLSMR). The MLSMR is screened with
biological assays or bioactivity experi-
ments looking for particular areas of bio-
logical activity.
Small molecule probes can be targeted
to interact with extreme precision with a
cell or cell byproduct. This specificity pro-
vides useful details about the steps in a
cell’s function and ultimately to its disease
pathway.A ‘‘truepositiveactive’’compound
found tobeactive against abiological target
is classified as a chemical probe.
As part of the MLP mandate, all identi-
fied probes are immediately reported to
the National Library of Medicine’s Pub-
Chem, a chemical and biological activity
repository. Full results may be withheld
for up to year to allow investigators to
publish their findings.
Though only 350,000 of the 26 million
unique chemical structures found in Pub-Chemistry & Biology 17, June 25, 2010Chem derive from the MLP, they have
generated a wealth of information when
combined with the biological assays also
deposited. Each participating MLP center
receives the screening library and uses it
to test a variety of biological questions.
‘‘The result is that over 90 million unique
biological results have been placed in
PubChem from the MLP sites, represent-
ing over 80% of the total,’’ explains Steve
Bryant, Ph.D., Program Director, Pub-
Chem. ‘‘It’s the combination of the
screening library with the unique bioas-
says that provide the information that
lead to the designation of probe.’’
All of the centers deposit the entire
screening experiment, even if most of
the results showed no activity or low
activity. ‘‘It’s important to know what
doesn’t work as well as what does,’’
explains Bryant.
Before victory is proclaimed, however,
a probe has to be validated. Enrique Mi-
chelotti, Ph.D., who oversees this process
within theMLP, says, ‘‘The assays and the
probes identified have to address a very
specific problem in biology.’’ Assay pro-
viders need to supply the proposed assay
to NIH for peer-review. The network
runs the assay through high throughput
screening against the 350,000 compound
MLSMR collection. ‘‘Any new compound
that is active in that assay is followed up
by chemistry and has to be best in class
in that it is addressing some particular
issue in biology,’’ he says. ‘‘That is what
we are looking for in a probe.’’
One hundred fifty validated probes
have been created since the $70 million,
4 year production phase of the effort
began in 2008, but only about 120 are
publicly available due to the 1 year
embargo. Full details on the available
probes can be found at the MLP website
(http://mli.nih.gov/mli/).
Screening, Et Al.
The data coming from the MLP includes
information on the chemical structuresª2010 Elsevier Ltd All rights reserved 549
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‘‘This lends real value to the program
because each center in the MLP has
a particular area of expertise regarding
types of assays used or areas of
research,’’ says Loomis.
But the MLP includes a bit more than
small molecule screening. It also funds
technology development encompassing
new instrumentation, chemical diversity
efforts includingnatural productsmethods,
and pilot scale libraries to generate novel
new compounds to put into the screening
library. For example, researchers at the
University of New Mexico, an MLP center,
are adapting flow cytometry to high
throughput screening.
Probe = Research Tool
MLP defines a probe as a compound that
can be useful as a research tool. ‘‘It does
not have to work in animals but ideally it
will work in cells,’’ explains Loomis. ‘‘It550 Chemistry & Biology 17, June 25, 2010 ªcould be a biochemical assay looking for
ameans toblocka compound’s phosphor-
ylation ability, or phenotypic assays.’’ The
latter are of very high value to the MLP
because these screens might point the
way in finding a better target for a pathway.
The MLP emphasizes rare and ne-
glected diseases, but they cover a large
range of therapeutic areas including
cancer, inflammation, infectious disease,
and metabolic diseases. However, MLP
funding is limited to the probe discovery
process only. ‘‘If, with a little more study,
some of these probes are found to be
useful in animals and eventually becomes
a lead for chemistry to develop a drug,
that is a win/win for us, but our funding
won’t go that far,’’ adds Loomis. If a probe
discoverer believes it may represent a
great opportunity for drug development,
alternative funding is necessary.
‘‘In my view, the most interesting and
valuable part of the MLP program is the
number of assays we have spanning2010 Elsevier Ltd All rights reservedmultiple therapeutic areas or potential
targets,’’ says Michelotti. In MLP, the
assays are designed in a way to capture
multiple levels of biological activity. ‘‘They
also include information on potential roles
of agonists, antagonists, partial agonists,
etc., as the informationwereceive isdenser,
more rich, because it is not limited to one
particular target.’’ And even within one
target, Michelotti points out that the biolog-
ical information is more comprehensive.
In the short time since full probe
production began in September 2008,
the MLP has become a go-to public
resource in the burgeoning field of chem-
ical probe production. With at least two
more years of guaranteed funding, the
number of new targets identified—and
the probes to accompany them—will
only rise in the hopes of quickening highly
targeted drug discovery.
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